<DOC>
	<DOCNO>NCT02477748</DOCNO>
	<brief_summary>This study multi-center , randomize , double-blind , placebo-controlled , phase 3 study MDX ( 1400 mg daily ) 10 week compare placebo adult ADHD . The study comprise Screening , Washout ( require ) , Treatment ( total 10 week ) Follow-up period . Approximately 750 patient enrol undergo initial eligibility assessment .</brief_summary>
	<brief_title>The MEASURE Study - A Phase 3 Study MDX 1400 mg Daily Compared With Placebo Adults With ADHD</brief_title>
	<detailed_description>- A 10-week randomized , multi-center , double-blind , placebo-controlled , phase 3 study MDX ( 1400 mg daily ) 10 week compare placebo adult ADHD . - The study comprise Screening , Washout ( require ) , Treatment ( total 10 week ) Follow-up period . Approximately 750 patient enrol undergo initial eligibility assessment . - Subjects require washout undergo Washout period ADHD medication discontinue ( 21 day atomoxetine , 14 day ADHD medication ) . These subject Interim Visit ( drug ) Day -10 ( Day -10 Day -3 ) CAARS-Inv assessment end Washout period . - Subjects randomly assign placebo/MDX total treatment duration ten week . There one week Follow-up period last dose study treatment early termination .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<criteria>1 . Subject man nonpregnant , nonlactating woman 18 55 year age , inclusive , Screening visit . 2 . Subject diagnosis ADHD base criterion Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) assess Adult ADHD Clinician Diagnostic Scale , ( ACDS Version 1.2 ) modify DSMIV DSM5 diagnose ; diagnosis ADHD otherwise specify unacceptable . 3 . Male Female subject childbearing potential must agree use effective contraceptive throughout study 4 . Subject able attend clinic regularly reliably . 5 . Subject able swallow tablet capsule . 6 . Subject able understand , read , write , speak local language fluently complete studyrelated material . 7 . Subject able understand sign inform consent form participate study . Exclusion criteria 1 . Subject current major psychiatric condition ( e.g. , schizophrenia , bipolar personality disorder ) autism spectrum disorder . 2 . Subject clinically significant unstable medical surgical condition may preclude safe complete study participation . 3 . Subject use investigational medication/treatment enrol another clinical trial 30 day Screening visit . 4 . Subject used medication food supplement investigator medical monitor consider unacceptable 14day period Baseline visit . 5 . Subject 's alcohol caffeine intake assess . 6 . Subject current suicidality , define active ideation , intent plan , significant lifetime suicidal behavior ( actual attempt , abort attempt , interrupt attempt , act preparation towards imminently make suicide attempt ) . Subjects exhibit history ( within previous 12 month ) nonsuicidal selfinjurious behavior exclude . 7 . Subject take prescription nonprescription medication ADHD 14 day ( 21 day atomoxetine ) Baseline visit . Subjects allowed take medication ADHD besides study medication ( prescribe ) washout period duration study , include safety Followup visit . ( Other ADHD medication NOT prescribed subject completion Followup visit Early Termination Visit ) . 8 . Subject significantly visually impaired extent able correct prescription glass contact lens . 9 . Subject closely related sponsor , investigator , study staff . Eligibility subject relationship sponsor , investigator , study staff discuss medical monitor study entry , medical monitor decide eligibility case . 10 . Subject previously enrol MDX clinical trial . 11 . Subject live household another subject clinical trial another ongoing trial MDX . Subject live household someone previously participate trial MDX . 12 . Subject condition , principal investigator 's opinion , would place subject risk influence conduct study interpretation result , include ( limited ) abnormally low intellectual capacity judge investigator . 13 . Subject fully comprehend implication protocol , comply requirement , incapable follow study schedule reason . 14 . Subject pregnant , lactating , use inadequate contraceptive method . Complete entry criterion review evaluate individually protocol trained delegate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>